Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apitegromab in later-onset SMA with background nusinersen or risdiplam
NCT05156320Phase 3Completed
- Sponsor
- Scholar Rock
- Start
- Apr 2022
- Primary completion
- Dec 2024
- Modality
- Monoclonal Antibodies
- Countries
- 9
01
Overview
Phase 3, randomised, double-blind trial of apitegromab in spinal muscular atrophy (SMA) (5 arms), sponsored by Scholar Rock. Primary endpoint: Hammersmith Functional Motor Scale Expanded at 12 months. Started Apr 2022; status: completed.
02
Drugs
apitegromab
03
Conditions
spinal muscular atrophy (SMA)
Beyond the preview
Go deeper on NCT05156320.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05156320.